Search

Your search keyword '"Rosmorduc, Olivier"' showing total 26 results
Start Over Author "Rosmorduc, Olivier" Publication Year Range Last 3 years
26 results on '"Rosmorduc, Olivier"'

2. Immune checkpoints are predominantly co-expressed by clonally expanded CD4+FoxP3+ intratumoral T-cells in primary human cancers

Author

Bredel, Delphine, Tihic, Edi, Mouraud, Séverine, Danlos, François-Xavier, Susini, Sandrine, Aglave, Marine, Alfaro, Alexia, Mohamed-Djalim, Chifaou, Rouanne, Mathieu, Halse, Héloise, Bigorgne, Amélie, Tselikas, Lambros, Dalle, Stéphane, Hartl, Dana M., Baudin, Eric, Guettier, Catherine, Vibert, Eric, Rosmorduc, Olivier, Robert, Caroline, Ferlicot, Sophie, Parier, Bastien, Albiges, Laurence, de Montpreville, Vincent Thomas, Besse, Benjamin, Mercier, Olaf, Even, Caroline, Breuskin, Ingrid, Classe, Marion, Radulescu, Camélia, Lebret, Thierry, Pautier, Patricia, Gouy, Sébastien, Scoazec, Jean-Yves, Zitvogel, Laurence, Marabelle, Aurélien, and Bonvalet, Mélodie

Published
2023
Full Text
View/download PDF

3. Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO – PRODIGE 82)

Author

Vienot, Angélique, Jacquin, Marion, Rebucci-Peixoto, Magali, Pureur, Dimitri, Ghiringhelli, François, Assenat, Eric, Hammel, Pascal, Rosmorduc, Olivier, Stouvenot, Morgane, Allaire, Manon, Bouattour, Mohamed, Regnault, Hélène, Fratte, Serge, Raymond, Eric, Soularue, Emilie, Husson-Wetzel, Stéphanie, Di Martino, Vincent, Muller, Allison, Clairet, Anne-Laure, Fagnoni-Legat, Christine, Adotevi, Olivier, Meurisse, Aurélia, Vernerey, Dewi, and Borg, Christophe

Published
2023
Full Text
View/download PDF

4. Biliary tract cancers: French national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT)

Author

Roth, Gael S., Verlingue, Loic, Sarabi, Matthieu, Blanc, Jean-Frédéric, Boleslawski, Emmanuel, Boudjema, Karim, Bretagne-Bignon, Anne-Laure, Camus-Duboc, Marine, Coriat, Romain, Créhange, Gilles, De Baere, Thierry, de la Fouchardière, Christelle, Dromain, Clarisse, Edeline, Julien, Gelli, Maximiliano, Guiu, Boris, Horn, Samy, Laurent-Croise, Valérie, Lepage, Côme, Lièvre, Astrid, Lopez, Anthony, Manfredi, Sylvain, Meilleroux, Julie, Neuzillet, Cindy, Paradis, Valérie, Prat, Frédéric, Ronot, Maxime, Rosmorduc, Olivier, Cunha, Antonio Sa, Soubrane, Olivier, Turpin, Anthony, Louvet, Christophe, Bouché, Olivier, and Malka, David

Published
2024
Full Text
View/download PDF

8. TOP-005 Immune checkpoint inhibitors after liver transplantation: the key role of immunosuppression management

Author

De Martin, Eleonora, primary, Antonini, Teresa, additional, Ningarhari, Massih, additional, Hilleret, Marie-Noëlle, additional, Allaire, Manon, additional, Del Bello, Arnaud, additional, Amaddeo, Giuliana, additional, Besch, Camille, additional, Cransac, Martine Neau, additional, Jaillais, Anais, additional, Ollivier-Hourmand, Isabelle, additional, Dharancy, Sébastien, additional, Decaens, Thomas, additional, Conti, Filomena, additional, Saliba, Faouzi, additional, Rosmorduc, Olivier, additional, Dumortier, Jérôme, additional, and Coilly, Audrey, additional

Published
2024
Full Text
View/download PDF

9. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

Author

Yau, Thomas, Park, Joong-Won, Finn, Richard S, Cheng, Ann-Lii, Mathurin, Philippe, Edeline, Julien, Kudo, Masatoshi, Harding, James J, Merle, Philippe, Rosmorduc, Olivier, Wyrwicz, Lucjan, Schott, Eckart, Choo, Su Pin, Kelley, Robin Kate, Sieghart, Wolfgang, Assenat, Eric, Zaucha, Renata, Furuse, Junji, Abou-Alfa, Ghassan K, El-Khoueiry, Anthony B, Melero, Ignacio, Begic, Damir, Chen, Gong, Neely, Jaclyn, Wisniewski, Tami, Tschaika, Marina, and Sangro, Bruno

Published
2022
Full Text
View/download PDF

12. Immune Checkpoints are Predominantly Co-Expressed by Clonally Expanded CD4+FoxP3+ Intratumoral T-cells in Primary Human Cancers

Author

Bredel, Delphine, primary, Tihic, Edi, additional, Mouraud, Séverine, additional, Danlos, François-Xavier, additional, Susini, Sandrine, additional, Aglave, Marine, additional, Alfaro, Alexia, additional, Mohamed-Djalim, Chifaou, additional, Rouanne, Mathieu, additional, Bigorgne, Amélie, additional, Tselikas, Lambros, additional, Dalle, Stéphane, additional, Hartl, Dana M, additional, Baudin, Eric, additional, Guettier, Catherine, additional, Vibert, Eric, additional, Rosmorduc, Olivier, additional, Robert, Caroline, additional, Ferlicot, Sophie, additional, Parier, Bastien, additional, Albiges, Laurence, additional, de Montpreville, Vincent Thomas, additional, Besse, Benjamin, additional, Mercier, Olaf, additional, Even, Caroline, additional, Breuskin, Ingrid, additional, Classe, Marion, additional, Radulescu, Camélia, additional, Lebret, Thierry, additional, Pautier, Patricia, additional, Gouy, Sébastien, additional, Scoazec, Jean-Yves, additional, Zitvogel, Laurence, additional, Marabelle, Aurelien, additional, and Bonvalet, Melodie, additional

Published
2023
Full Text
View/download PDF

13. Supplementary Tables and Figures from Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial

Author

Zhu, Andrew X., primary, Kang, Yoon-Koo, primary, Rosmorduc, Olivier, primary, Evans, T.R. Jeffry, primary, Santoro, Armando, primary, Ross, Paul, primary, Gane, Edward, primary, Vogel, Arndt, primary, Jeffers, Michael, primary, Meinhardt, Gerold, primary, and Peña, Carol E.A., primary

Published
2023
Full Text
View/download PDF

14. Supplementary Tables and Figures TC from Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial

Author

Zhu, Andrew X., primary, Kang, Yoon-Koo, primary, Rosmorduc, Olivier, primary, Evans, T.R. Jeffry, primary, Santoro, Armando, primary, Ross, Paul, primary, Gane, Edward, primary, Vogel, Arndt, primary, Jeffers, Michael, primary, Meinhardt, Gerold, primary, and Peña, Carol E.A., primary

Published
2023
Full Text
View/download PDF

15. Supplementary Data from Insulin-Like Growth Factor-1 Receptor Inhibition Induces a Resistance Mechanism via the Epidermal Growth Factor Receptor/HER3/AKT Signaling Pathway: Rational Basis for Cotargeting Insulin-Like Growth Factor-1 Receptor and Epidermal Growth Factor Receptor in Hepatocellular Carcinoma

Author

Desbois-Mouthon, Christèle, primary, Baron, Aurore, primary, Blivet-Van Eggelpoël, Marie-José, primary, Fartoux, Laetitia, primary, Venot, Corinne, primary, Bladt, Friedhelm, primary, Housset, Chantal, primary, and Rosmorduc, Olivier, primary

Published
2023
Full Text
View/download PDF

16. Supplementary Figure S4 from Mitogenic Insulin Receptor-A Is Overexpressed in Human Hepatocellular Carcinoma due to EGFR-Mediated Dysregulation of RNA Splicing Factors

Author

Chettouh, Hamza, primary, Fartoux, Laetitia, primary, Aoudjehane, Lynda, primary, Wendum, Dominique, primary, Clapéron, Audrey, primary, Chrétien, Yves, primary, Rey, Colette, primary, Scatton, Olivier, primary, Soubrane, Olivier, primary, Conti, Filomena, primary, Praz, Françoise, primary, Housset, Chantal, primary, Rosmorduc, Olivier, primary, and Desbois-Mouthon, Christèle, primary

Published
2023
Full Text
View/download PDF

17. Supplementary Figure Legends from Mitogenic Insulin Receptor-A Is Overexpressed in Human Hepatocellular Carcinoma due to EGFR-Mediated Dysregulation of RNA Splicing Factors

Author

Chettouh, Hamza, primary, Fartoux, Laetitia, primary, Aoudjehane, Lynda, primary, Wendum, Dominique, primary, Clapéron, Audrey, primary, Chrétien, Yves, primary, Rey, Colette, primary, Scatton, Olivier, primary, Soubrane, Olivier, primary, Conti, Filomena, primary, Praz, Françoise, primary, Housset, Chantal, primary, Rosmorduc, Olivier, primary, and Desbois-Mouthon, Christèle, primary

Published
2023
Full Text
View/download PDF

18. Data from Mitogenic Insulin Receptor-A Is Overexpressed in Human Hepatocellular Carcinoma due to EGFR-Mediated Dysregulation of RNA Splicing Factors

Author

Chettouh, Hamza, primary, Fartoux, Laetitia, primary, Aoudjehane, Lynda, primary, Wendum, Dominique, primary, Clapéron, Audrey, primary, Chrétien, Yves, primary, Rey, Colette, primary, Scatton, Olivier, primary, Soubrane, Olivier, primary, Conti, Filomena, primary, Praz, Françoise, primary, Housset, Chantal, primary, Rosmorduc, Olivier, primary, and Desbois-Mouthon, Christèle, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Tables S1-S5 from Mitogenic Insulin Receptor-A Is Overexpressed in Human Hepatocellular Carcinoma due to EGFR-Mediated Dysregulation of RNA Splicing Factors

Author

Chettouh, Hamza, primary, Fartoux, Laetitia, primary, Aoudjehane, Lynda, primary, Wendum, Dominique, primary, Clapéron, Audrey, primary, Chrétien, Yves, primary, Rey, Colette, primary, Scatton, Olivier, primary, Soubrane, Olivier, primary, Conti, Filomena, primary, Praz, Françoise, primary, Housset, Chantal, primary, Rosmorduc, Olivier, primary, and Desbois-Mouthon, Christèle, primary

Published
2023
Full Text
View/download PDF

20. Value of 18-F fluorodeoxyglucose/choline positron emission tomography imaging for predicting hepatocellular carcinoma recurrence after liver transplantation

Author

Pascale, Alina, primary, Besson, Florent, additional, Golse, Nicolas, additional, Guettier, Catherine, additional, Lewin, Maite, additional, Duclos-Vallée, Jean-Charles, additional, Sobesky, Rodolphe, additional, De Martin, Eleonora, additional, Poli, Edoardo, additional, Kounis, Ilias, additional, Duhaut, Lea, additional, Merabet, Yasmina Ben, additional, Roche, Bruno, additional, Antonini, Tereza, additional, Saliba, Faouzi, additional, Ichai, Philippe, additional, Boudon, Marc, additional, Sacleux, Sophie, additional, Ordan, Marie-Amelie, additional, Allard, Marc Antoine, additional, Pittau, Gabriella, additional, Ciacio, Oriana, additional, Cunha, Antonio Sa, additional, Azoulay, Daniel, additional, Adam, René, additional, Vibert, Eric, additional, Cherqui, Daniel, additional, Coilly, Audrey, additional, Rosmorduc, Olivier, additional, and Samuel, Didier, additional

Published
2022
Full Text
View/download PDF

21. Place of steroids and prognosis factors for grade = 3 immune-checkpoint inhibitors induced hepatitis: a 6-year prospective study

Author

De Martin, Eleonora, primary, Lutu, Alina, additional, Laparra-Ramakichenin, Ariane, additional, Golse, Nicolas, additional, Bellue, Astrid Laurent, additional, Robert, Caroline, additional, Lambotte, Olivier, additional, Coilly, Audrey, additional, Kounis, Ilias, additional, Poli, Edoardo, additional, Duhaut, Lea, additional, Rosmorduc, Olivier, additional, Guettier, Catherine, additional, Michot, Jean-Marie, additional, and Samuel, Didier, additional

Published
2022
Full Text
View/download PDF

22. Advanced epithelioid hemangioendothelioma of the liver: could lenvatinib offer a bridge treatment to liver transplantation?

Author

UCL - SSS/IREC - Institut de recherche expérimentale et clinique, Kounis, Ilias, Lewin, Maïté, Laurent-Bellue, Astrid, Poli, Edoardo, Coilly, Audrey, Duclos-Vallée, Jean-Charles, Guettier, Catherine, Adam, René, Lerut, Jan, Samuel, Didier, Rosmorduc, Olivier, UCL - SSS/IREC - Institut de recherche expérimentale et clinique, Kounis, Ilias, Lewin, Maïté, Laurent-Bellue, Astrid, Poli, Edoardo, Coilly, Audrey, Duclos-Vallée, Jean-Charles, Guettier, Catherine, Adam, René, Lerut, Jan, Samuel, Didier, and Rosmorduc, Olivier

Abstract

In this article, we describe the case of a 34-year-old woman presenting a multifocal and metastatic epithelioid hemangioendothelioma (HEHE) of the liver. Under classical chemotherapy using cyclophosphamide, there was a fast tumor progression in liver and extra-hepatic metastatic sites (lungs and mediastinal lymph node). Taking into account the patient's age and the natural history of the HEHE, our goal was to try to bring her to liver transplantation (LT) and lenvatinib was an acceptable candidate for this reason. Shortly after the initiation of lenvatinib before LT and surgery, we observed the enlargement of large devascularized necrotic areas in most of the liver HEHE masses, suggesting a good response. The patient was finally transplanted 6 months after initiation of lenvatinib treatment. Eight months after LT, progression occurred (ascites, peritoneal recurrence, and mediastinal lymph node). After restarting lenvatinib, ascites disappeared and the lymph node decreased in size, suggesting a good response, more than 1 year after her transplantation. This is the first case report to our knowledge that illustrates the benefit of lenvatinib as a neoadjuvant bridge until LT for a multifocal and metastatic HEHE. In addition, this drug has also shown a benefit in term of disease control after a late recurrence of the tumor. We suggest that lenvatinib should be proposed as a bridge to the LT for nonresectable HEHE. Moreover, this drug was also beneficial in the treatment of late recurrence after LT. The absence of pharmacologic interactions between classical immunosuppressive drugs and lenvatinib may allow its use as an early adjuvant approach when the risk of recurrence is high. The strength of our case consists in the long follow-up and the innovative message allowing changing palliative strategies into curative ones in case of advanced HEHE.

Published
2022

23. Advanced epithelioid hemangioendothelioma of the liver: could lenvatinib offer a bridge treatment to liver transplantation?

Author

Kounis, Ilias, primary, Lewin, Maïté, additional, Laurent-Bellue, Astrid, additional, Poli, Edoardo, additional, Coilly, Audrey, additional, Duclos-Vallée, Jean-Charles, additional, Guettier, Catherine, additional, Adam, René, additional, Lerut, Jan, additional, Samuel, Didier, additional, and Rosmorduc, Olivier, additional

Published
2022
Full Text
View/download PDF

24. SAT595 - Value of 18-F fluorodeoxyglucose/choline positron emission tomography imaging for predicting hepatocellular carcinoma recurrence after liver transplantation

Author

Pascale, Alina, Besson, Florent, Golse, Nicolas, Guettier, Catherine, Lewin, Maite, Duclos-Vallée, Jean-Charles, Sobesky, Rodolphe, De Martin, Eleonora, Poli, Edoardo, Kounis, Ilias, Duhaut, Lea, Merabet, Yasmina Ben, Roche, Bruno, Antonini, Tereza, Saliba, Faouzi, Ichai, Philippe, Boudon, Marc, Sacleux, Sophie, Ordan, Marie-Amelie, Allard, Marc Antoine, Pittau, Gabriella, Ciacio, Oriana, Cunha, Antonio Sa, Azoulay, Daniel, Adam, René, Vibert, Eric, Cherqui, Daniel, Coilly, Audrey, Rosmorduc, Olivier, and Samuel, Didier

Published
2022
Full Text
View/download PDF

25. Indocyanine green fluorescence patterns of hepatocellular carcinoma correlate with pathological and molecular features.

Author

Sebagh, Mylène, Desterke, Christophe, Feray, Cyrille, Hamelin, Jocelyne, Habib, Myriam, Samuel, Didier, Rosmorduc, Olivier, Vibert, Eric, and Golse, Nicolas

Subjects
*INDOCYANINE green, *HEPATOCELLULAR carcinoma, *FLUORESCENCE, *MACHINE learning, *GENETIC mutation, *TUMOR classification
Abstract

Intraoperative Indocyanine Green Dye (ICG) routinely used in hepatobiliary surgery identifies different fluorescent patterns of hepatocellular carcinoma (HCC), a highly heterogeneous cancer. We aimed to correlate these patterns with gene mutations and extensive pathological features beyond the well-known tumor differentiation. Between February 2017 and December 2019, 21 HCC in 16 consecutive patients who underwent intraoperative ICG fluorescence imaging were included. Pathological review was performed by one pathologist blinded to fluorescence features. Random forest machine learning algorithm correlated pathological features of the tumor, peritumoral and non-tumoral liver, and gene mutations from a 28 gene-panel with rim and intra-lesion fluorescence. Three HCC had negative intra-lesion and rim-like emission, 7 HCC had homogeneous pattern and 11 heterogeneous patterns in whom 3 with rim-like emission. Rim emission was associated with peritumoral vascular changes, lower differentiation and lower serum AFP level. Homogeneous intra-lesion fluorescence was associated with lower necrosis rate, thinner capsule, absence of peritumoral liver changes, and higher serum AFP level. Heterogeneous HCC without rim harbored lesser TP53 and ARID1A mutations. Tumoral and peri-tumoral fluorescence classification of HCC yielded a possible intraoperative pathological and molecular characterization. These preliminary observations could lead to intraoperative refinement in surgical strategy. The fluorescent patterns of hepatocellular carcinoma using Indocyanine Green Dye were associated with various pathological features beyond the well-known correlation with tumor differentiation, and with gene mutations. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

26. Unresectable hepatocellular carcinoma at dawn of immunotherapy era: real-world data from the French prospective CHIEF cohort.

Author

Nguyen-Khac E, Nahon P, Ganry O, Ben Khadhra H, Merle P, Amaddeo G, Ganne-Carrie N, Silvain C, Peron JM, Mathurin P, Anty R, Uguen T, Decaens T, Riachi G, Bouattour M, Baron A, Bronowicki JP, Pageaux GP, Rosmorduc O, Ducournau G, Gilberg M, Tanang A, Dupin J, Gilbert-Marceau A, and Blanc JF

Subjects
Humans, Bevacizumab adverse effects, Retrospective Studies, Quality of Life, Prospective Studies, Immunotherapy adverse effects, Carcinoma, Hepatocellular therapy, Carcinoma, Hepatocellular drug therapy, Liver Neoplasms therapy, Liver Neoplasms drug therapy, Chemoembolization, Therapeutic adverse effects, Chemoembolization, Therapeutic methods
Abstract

Background and Objectives: Hepatocellular carcinoma epidemiological data are limited in France. The Epidemio Liver Immunotherapy Tecentriq outcome research (ELITor) retrospective study, based on real-world data from the Carcinome HépatocellulaIrE en France (CHIEF) French cohort of hepatocellular carcinoma patients, aimed to get insight into the treatment patterns, the sociodemographic, clinical, biological, and etiological characteristics, and the quality of life of patients with unresectable hepatocellular carcinoma., Methods and Results: Between 1 September 2019 and 4 December 2020, 367 patients from the CHIEF cohort received at least one locoregional (52.8%) chemoembolization or radioembolization or systemic treatment (88.3%) and were selected for ELITor. Most patients had a Barcelona Clinic Liver Cancer (BCLC) C (93.2%) hepatocellular carcinoma stage and were affected by cirrhosis (67.7%). Alcohol was confirmed as the main etiology both as a single etiology (29.1%) and in association with other risk factors (26.9%), mainly metabolic disorders (16.2%).Tyrosine-kinase inhibitors, mainly sorafenib, were the most administered systemic treatments in first line. Patients who received at least one combination of atezolizumab and bevacizumab during the study period ( N  = 53) had a better performance status and less portal hypertension frequency than the overall population and more hepatitis B virus infection and fewer metabolic disorders as single etiology. Overall, the global health score before treatment (62.3 ± 21.9) was in line with that of reference cancer patients and worsened in 51.9% of the cases after first-line palliative-intent treatment., Conclusion: This study provided real-life data on advanced hepatocellular carcinoma characteristics and treatment patterns and described the first patients to receive the atezolizumab-bevacizumab combination before it became the new standard of care for advanced hepatocellular carcinoma., (Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results